ORGS Key Statistics, Chart & Performance
The current stock price of ORGS is 2.11 USD. In the past month the price decreased by -59.22%. In the past year, price decreased by -76.89%.
ORGS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.43 | 391.33B | ||
| AMGN | AMGEN INC | 14.97 | 176.33B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.63B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.94 | 118.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.33B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.47 | 52.79B | ||
| INSM | INSMED INC | N/A | 37.14B | ||
| NTRA | NATERA INC | N/A | 33.82B | ||
| BIIB | BIOGEN INC | 10.78 | 26.46B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.1 | 21.71B | ||
| INCY | INCYTE CORP | 16.64 | 20.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About ORGS
Company Profile
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 146 full-time employees. The company went IPO on 2010-07-01. The firm focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. The company operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Company Info
ORGENESIS INC
20271 Goldenrod Lane
Germantown MARYLAND 20876 US
CEO: Vered Caplan
Employees: 146
Phone: 14806596404
ORGENESIS INC / ORGS FAQ
What does ORGENESIS INC do?
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 146 full-time employees. The company went IPO on 2010-07-01. The firm focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. The company operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
What is the stock price of ORGENESIS INC today?
The current stock price of ORGS is 2.11 USD. The price decreased by -34.84% in the last trading session.
What is the dividend status of ORGENESIS INC?
ORGS does not pay a dividend.
What is the ChartMill rating of ORGENESIS INC stock?
ORGS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for ORGENESIS INC?
ORGENESIS INC (ORGS) has a market capitalization of 10.06M USD. This makes ORGS a Nano Cap stock.
When does ORGENESIS INC (ORGS) report earnings?
ORGENESIS INC (ORGS) will report earnings on 2024-11-11, before the market open.
ORGS Technical Analysis
ORGS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ORGS. ORGS may be in some trouble as it scores bad on both profitability and health.
ORGS Financial Highlights
Over the last trailing twelve months ORGS reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by -125.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ORGS Forecast & Estimates
7 analysts have analysed ORGS and the average price target is 6.12 USD. This implies a price increase of 190.05% is expected in the next year compared to the current price of 2.11.
For the next year, analysts expect an EPS growth of 190.48% and a revenue growth 39.76% for ORGS